[Federal Register Volume 74, Number 180 (Friday, September 18, 2009)]
[Notices]
[Pages 47929-47930]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-22554]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Provisional Patent Application Concerning Novel Use 
and Method of Rapamycin To Treat Toxic Shock

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/045,184 entitled ``Novel Use and Method of Rapamycin to Treat Toxic 
Shock,'' filed August 5, 2009. The United States Government, as 
represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Assessment, (301) 619-6664, 
both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to the use of 
Rapamycin as a treatment of toxic shock

[[Page 47930]]

induced by staphylococcal exotoxins; more specifically, staphylococcal 
enterotoxins that are potent activators for human T cells and can cause 
lethal shock.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9-22554 Filed 9-17-09; 8:45 am]
BILLING CODE 3710-08-P